Nexstim Plc · OMXHEX:NXTMH
Nexstim — Biotech Showcase 2017
24 slides from Nexstim's conference presentation, Jan 11, 2017
Slide 1: Targeting a paradigm shift in stroke rehabilitation
Targeting a paradigm shift in stroke rehabilitation Martin Jamieson| CEO & Chairman of the Board | Nexstim Mikko Karvinen| CFO | Nexstim Biotech Showcase, San Francisco, 11 January 2017 @NexstimOyj
Slide 2: Important information
Important information This document and the information contained herein are being presented by Nexstim Oyj Certain of the information contained herein concerning industry and market data, economic (“Nexstim” or the “Company”). In connection with any presentation or review of this trends, market pos
Slide 3: Nexstim Plc at a Glance
Nexstim Plc at a Glance ● Pioneering navigated brain stimulation technology (nTMS) ● Experienced management and international Board ● Listed in Nasdaq First North Finland & Sweden ● Offices in Finland, US and Germany ● Established in 2000 3
Slide 4: Nexstim Transcranial Magnetic Stimulation (TMS) platform
Nexstim Transcranial Magnetic Stimulation (TMS) platform Diagnostic Therapy Navigated Brain Stimulation (NBS) Navigated Brain Therapy (NBT®) 4
Slide 5: Platform protected with 27 patent families
Platform protected with 27 patent families ● 89 granted patents, 61 pending ● Right to software: Nexstim owns rights to its NBT® and NBS Systems’ software developed in-house. ● Core algorithms kept as trade secrets 5
Slide 6: Navigated Brain Stimulation for pre-surgical mapping of brain tumours
Navigated Brain Stimulation® for pre-surgical mapping of brain tumours @NexstimOyj
Slide 7: NBS Pre-Surgical Mapping Overview
NBS Pre-Surgical Mapping Overview ● Non-invasive system for mapping the Motor and Speech Cortex prior to tumour surgery ● Navigation is the key to accurate mapping ● The NBS system links ● Brain anatomy (MRI) ● Location of the E-Field induced by TMS (navigation) ● Muscle response (EMG) ● Seamless wo
Slide 8: NBS vs. Direct Cortical Stimulation (DCS) motor mapping
NBS vs. Direct Cortical Stimulation (DCS) motor mapping Nexstim’sNBS DCS - Current ”gold standard” Non-invasive Invasive Mapping possible days or weeks prior to Mapping during surgery surgery 8
Slide 9: NBS Pre-Surgical Mapping makes the difference to clinical outcome
NBS Pre-Surgical Mapping makes the difference to clinical outcome Progression-free Survival (Months) Direct Cortical 46% Increase in Stimulation PFS in Low Grade Gliomas1 NBS + Direct Cortical Stimulation 0 5 10 15 20 25 1 Dietmar Frey, Peter Vajkoczy, and Thomas Picht Navigated transcranial magneti
Slide 10: NBS Pre-Surgical Mapping Major Centers
NBS Pre-Surgical Mapping Major Centers 10
Slide 11: Navigated Brain Therapy
Navigated Brain Therapy® @NexstimOyj
Slide 12: NBT has potential for multiple therapeutic applications due to precise navigation
NBT® (Navigated Brain Therapy) has potential for multiple therapeutic applications due to precise navigation Primary motor cortex Primary motor/sensory cortex (stroke rehabilitation therapy) (pain therapy) Dorsolateral prefrontal cortex (depression therapy) Temporoparietal cortex (therapy for audito
Slide 13: NBT for stroke rehabilitation – how it works
NBT® for stroke rehabilitation – how it works Validated e-Field Navigation gives Competitive Edge Using a patient’s own MRI scan as a guide, Nexstim Because the injured side is no longer dominated by provides precisely targeted, personalized, the healthy side of the brain, it is more responsive magn
Slide 14: Market opportunity in stroke rehabilitation
Market opportunity in stroke rehabilitation 2015 Incidence of stroke 2015 Stroke survivors USA USA 0.8 M 6.5 M China China 15 M Europe 2.5 M (7.5 M)* Europe 1.2 M 8.0 M *Published data • Large and rapidly growing market • 50% of stroke survivors will have upper limb paralysis with few available trea
Slide 15: Clinical data comparing NBT + occupational therapy (OT) with OT
Clinical data comparing NBT® + occupational therapy (OT) with OT ● 199 patients – 12 leading US centres Phase III NICHE results >2/3 >2/3 ● Excellent results in active group Rate for clinically meaningful NBT® SHAM <1/3 ● Sham coil in control group proved active response +OT +OT OT ● Safety endorsed
Slide 16: Timeline of US Regulatory Development for Stroke
Timeline of US Regulatory Development for Stroke December February March April H2 2016 2017 2018 2018 2018 FDA approval of Expected Expected Expected Expected Trial Protocol Trial Trial FDA 510(k) FDA 510(k) Commence Completion de novo filing de novo clearance 16
Slide 17: Other indications
Other indications ● Chronic pain ● CE mark for treatment ● Chronic neuropathic pain trial with Nexstim’s NBT® has been completed. The study demonstrated 44% of patients obtained clinically meaningful pain relief of at least 3 weeks' duration ● Second study using Nexstim's technology at The Walton Ce
Slide 18: Key performance indicators
Key performance indicators EUR in thousands H1 2016 H1 2015 FY 2015 6 months 6 months 12 months Net sales increase of 38.8 percent Net sales 892.5 643.2 2,527.9 Personnel expenses -2,214.6 -1,906.1 -3,969.8 Includes EUR Depreciation and amortisation -168.8 -168.7 -386.0 1,227.4 thousand of Phase III
Slide 19: Nexstim Funding
Nexstim Funding ● Accelerated pace in the two year funding arrangement with Bracknor Investment and Finnish Innovation Fund Sitra ● Funding arrangement is a combination of: ● EUR 5 million of convertible bonds – 100% funded ● EUR 6.5 million stand-by equity facilities ~50% funded ● EUR 0.5 million d
Slide 20: Nexstim Strategic Actions
Nexstim Strategic Actions ● Move to distributor model in US for Pre-surgical mapping ● Focus on therapeutic applications – Primarily Stroke, Depression and Pain ● File 510(k) for depression during H1 2017 ● Exploit CE marked approval in Stroke – EU sales to begin in H1 2017 ● Stroke rehabilitation 5
Slide 21: Thank you
Thank you @NexstimOyj
Slide 22: The Board
Appendix The Board Name Education Relevant experience Nationality Martin Jamieson, Currently board member of C-Major Ltd, LightPoint University of the Arts (CDT) London 2015 Medical Ltd and Medway NHS Foundation Hospital Trust. Chairman Higher National Diploma - Business Studies Previously Managing
Slide 23: Management team
Appendix Management team Name Current position (Nexstim Education Relevant experience Nationality since) Currently board member of C-Major Ltd, University of the Arts (CDT) London LightPoint Medical Ltd and Medway NHS Martin Jamieson CEO & Chairman of the Board Higher National Diploma - Business Stu
Slide 24: Nexstim Active NICHE coil vs. SHAM coil
Nexstim Active NICHE coil vs. SHAM coil ● Nexstim Active Coil creates a cone –like magnetic field to ● Nexstim SHAM coil creates a donut-like magnetic field to induce the stimulating electric field. This allows NBT to be induce a weak stimulating electric field which is around accurate with stimulat